Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications
Acute Lymphoblastic Leukemia (ALL) is the predominant hematological malignancy in pediatric populations, originating from B- or T-cell precursors within the bone marrow. The disease exhibits a high degree of heterogeneity, both at the molecular level and in terms of clinical presentation. A complex...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1322937/full |
| _version_ | 1797401553273880576 |
|---|---|
| author | Alan Jhones Barbosa Assis Brunna Letícia de Oliveira Santana Ana Cristina Moura Gualberto Fabio Pittella-Silva |
| author_facet | Alan Jhones Barbosa Assis Brunna Letícia de Oliveira Santana Ana Cristina Moura Gualberto Fabio Pittella-Silva |
| author_sort | Alan Jhones Barbosa Assis |
| collection | DOAJ |
| description | Acute Lymphoblastic Leukemia (ALL) is the predominant hematological malignancy in pediatric populations, originating from B- or T-cell precursors within the bone marrow. The disease exhibits a high degree of heterogeneity, both at the molecular level and in terms of clinical presentation. A complex interplay between inherited and acquired genetic alterations contributes to disease pathogenesis, often resulting in the disruption of cellular functions integral to the leukemogenic process. The advent of CRISPR/Cas9 as a gene editing tool has revolutionized biological research, underscoring its potential to modify specific genomic loci implicated in cancer. Enhanced understanding of molecular alterations in ALL has facilitated significant advancements in therapeutic strategies. In this review, we scrutinize the application of CRISPR/Cas9 as a tool for identifying genetic targets to improve therapy, circumvent drug resistance, and facilitate CAR-T cell-based immunotherapy. Additionally, we discuss the challenges and future prospects of CRISPR/Cas9 applications in ALL. |
| first_indexed | 2024-03-09T02:11:45Z |
| format | Article |
| id | doaj.art-75e5be9540044ffbb3b9c067e18f0553 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-09T02:11:45Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-75e5be9540044ffbb3b9c067e18f05532023-12-07T08:54:57ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-12-011410.3389/fphar.2023.13229371322937Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implicationsAlan Jhones Barbosa AssisBrunna Letícia de Oliveira SantanaAna Cristina Moura GualbertoFabio Pittella-SilvaAcute Lymphoblastic Leukemia (ALL) is the predominant hematological malignancy in pediatric populations, originating from B- or T-cell precursors within the bone marrow. The disease exhibits a high degree of heterogeneity, both at the molecular level and in terms of clinical presentation. A complex interplay between inherited and acquired genetic alterations contributes to disease pathogenesis, often resulting in the disruption of cellular functions integral to the leukemogenic process. The advent of CRISPR/Cas9 as a gene editing tool has revolutionized biological research, underscoring its potential to modify specific genomic loci implicated in cancer. Enhanced understanding of molecular alterations in ALL has facilitated significant advancements in therapeutic strategies. In this review, we scrutinize the application of CRISPR/Cas9 as a tool for identifying genetic targets to improve therapy, circumvent drug resistance, and facilitate CAR-T cell-based immunotherapy. Additionally, we discuss the challenges and future prospects of CRISPR/Cas9 applications in ALL.https://www.frontiersin.org/articles/10.3389/fphar.2023.1322937/fullCRISPR/Cas9gene editingacute lymphoblastic leukemiatherapeutic strategies cancer treatmentcurrent perspectives |
| spellingShingle | Alan Jhones Barbosa Assis Brunna Letícia de Oliveira Santana Ana Cristina Moura Gualberto Fabio Pittella-Silva Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications Frontiers in Pharmacology CRISPR/Cas9 gene editing acute lymphoblastic leukemia therapeutic strategies cancer treatment current perspectives |
| title | Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications |
| title_full | Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications |
| title_fullStr | Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications |
| title_full_unstemmed | Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications |
| title_short | Therapeutic applications of CRISPR/Cas9 mediated targeted gene editing in acute lymphoblastic leukemia: current perspectives, future challenges, and clinical implications |
| title_sort | therapeutic applications of crispr cas9 mediated targeted gene editing in acute lymphoblastic leukemia current perspectives future challenges and clinical implications |
| topic | CRISPR/Cas9 gene editing acute lymphoblastic leukemia therapeutic strategies cancer treatment current perspectives |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1322937/full |
| work_keys_str_mv | AT alanjhonesbarbosaassis therapeuticapplicationsofcrisprcas9mediatedtargetedgeneeditinginacutelymphoblasticleukemiacurrentperspectivesfuturechallengesandclinicalimplications AT brunnaleticiadeoliveirasantana therapeuticapplicationsofcrisprcas9mediatedtargetedgeneeditinginacutelymphoblasticleukemiacurrentperspectivesfuturechallengesandclinicalimplications AT anacristinamouragualberto therapeuticapplicationsofcrisprcas9mediatedtargetedgeneeditinginacutelymphoblasticleukemiacurrentperspectivesfuturechallengesandclinicalimplications AT fabiopittellasilva therapeuticapplicationsofcrisprcas9mediatedtargetedgeneeditinginacutelymphoblasticleukemiacurrentperspectivesfuturechallengesandclinicalimplications |